Project Grant R01AG102887
- The National Institute on Aging awarded the University of Pittsburgh $619,577 on September 1, 2026, under the Aging Research program (CFDA 93.866) for statistical methods development in spatial proteogenomics data analysis applied to Alzheimer's disease research. The project develops computational and statistical methods to advance spatial proteogenomics analysis, which integrates spatially resolved protein and transcript information to examine cellular organization in brain tissue. In Aim 1,...
- The National Institute on Aging, a component of the Department of Health and Human Services, awarded Massachusetts Institute of Technology $596,050 on September 15, 2026, under the Aging Research program (CFDA 93.866) to investigate fuzzy coat dynamics of post-translationally modified tau aggregation. The project examines structural properties of tau, a microtubule-associated protein whose aggregation hallmarks Alzheimer's disease and twenty other neurodegenerative diseases. The research tests...
- The National Institute on Aging awarded the University of Pittsburgh $673,702 on September 1, 2026, under the Aging Research program (CFDA 93.866) to support research deciphering ubiquilin-mediated proteostasis mechanisms in Alzheimer's disease and related dementias. The research addresses knowledge gaps in ubiquilin function and protein homeostasis defects underlying neurodegenerative disease. The project will elucidate how STI1 domain binding and E3 ligase recruitment affect cellular fitness...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded $691,306 to Trustees of Indiana University (Indiana University Indianapolis) on August 15, 2026, under the Aging Research program (CFDA 93.866). The award funds research integrating real-world evidence from electronic medical records, cell line assays, and single-cell omics via deep reinforcement learning to identify repurposable drugs for Alzheimer's disease treatment. The project applies deep transfer...
- The National Institute on Aging, an office of the National Institutes of Health, awarded the University of California, Davis $683,331 under the Aging Research program (CFDA 93.866) on September 1, 2026, to identify and validate causal risk genes and proteins contributing to Alzheimer's disease and its neuropsychiatric symptoms. The research integrates genome-wide association study (GWAS) findings with functional omics data from post-mortem brain tissues to pinpoint proteins mediating Alzheimer's...
- The National Institute on Aging awarded Indiana University Indianapolis $109,795 on August 20, 2026, under the Aging Research program (CFDA 93.866) to evaluate amyloid dynamics and cerebral amyloid angiopathy burden. The project examines amyloid plaque redistribution and cerebral amyloid angiopathy development through genetic and pharmacological methods, and tests whether dietary and exercise interventions mitigate cerebral amyloid angiopathy burden. The research evaluates glial-based mechanisms...
- The National Institute on Aging awarded Purdue University $1,293,752 under project grant R01AG098151 on February 15, 2026, to develop generative artificial intelligence platforms for peptide drug design targeting Alzheimer's disease and related dementias. The project combines generative AI technologies with high-throughput data generation and in vitro/in vivo assays to design peptides that address key pharmaceutical challenges including limited permeability and stability. The work builds on...
- The National Institute on Aging awarded Northwestern University $457,112 on January 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of toxic short RNAs (sRNAs) and the DISE (Death Induced by Survival Elimination) mechanism in neurodegenerative diseases, particularly Alzheimer's disease and Huntington's disease. The research examines how G-rich sRNAs target survival genes through miRNA-like pathways and explores why normal tissues remain protected from this cell...
- The National Institute on Aging awarded Georgetown University $156,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate mitigation strategies for network dysfunction in Alzheimer's disease pathology. The project tests whether mild hyperpolarization can stabilize hippocampal network activity despite amyloid-beta-related impairment of excitatory amino acid transporters. The research quantifies sharp wave-ripples in ex vivo hippocampal slices from 5XFAD transgenic...
- The National Institute on Aging awarded $1,212,742 to the Sloan-Kettering Institute for Cancer Research on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate epichaperomes as a mechanism for restoring drug responsiveness in Alzheimer's disease. The research tests the hypothesis that epichaperome inhibition with PU-AD restores synaptic architecture and re-enables responsiveness to levetiracetam (LEV), a therapy whose efficacy depends on properly localized SV2A...
The National Institute on Aging awarded Purdue University $387,183 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop mass spectrometry-based proteomics strategies examining post-translational modifications related to protein aggregation and extracellular vesicle-mediated propagation in neurodegenerative disease, with emphasis on Alzheimer's disease. The recipient will establish a novel proteomics platform to profile N-terminal acetylation landscapes in primary neuron cells, induced pluripotent stem cells, brain tissues from Alzheimer's disease patients, and their secreted extracellular vesicles. The work pursues three specific aims: measurement of canonical and neo terminal acetylation stoichiometry of misfolded proteins in cells and extracellular vesicles; investigation of how impaired autophagy-lysosomal pathway affects protein N-terminal acetylation in primary neuron-secreted extracellular vesicles; and correlation of N-terminal acetylation stoichiometry of misfolded proteins in extracellular vesicles with disease stage and progression in Alzheimer's disease patients. Preliminary studies indicate that quantifying both canonical N-terminal acetylation and neo N-terminal acetylation stoichiometry may serve as indicators for disease onset and progression. Performance takes place in West Lafayette, Indiana. The period of performance extends from September 1, 2026, through May 31, 2031. This is a Project Grant, the standard assistance type under the National Institute on Aging's portfolio for biomedical, social, and behavioral research directed toward understanding aging and age-related diseases.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $387.2k | 8/31/26 |